COVID-19 studies are our top priority.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT01247324




Registration number
NCT01247324
Ethics application status
Date submitted
23/11/2010
Date registered
24/11/2010
Date last updated
17/12/2020

Titles & IDs
Public title
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
Scientific title
A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif®) in Patients With Relapsing Multiple Sclerosis
Secondary ID [1] 0 0
2010-020337-99
Secondary ID [2] 0 0
WA21092
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Relapsing Multiple Sclerosis 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Interferon beta-1a
Treatment: Drugs - Ocrelizumab-matching placebo
Treatment: Drugs - Ocrelizumab
Treatment: Drugs - Interferon beta-1a-matching placebo

Active Comparator: Interferon beta-1a 44 mcg SC - Interferon beta-1a 44 mcg SC injections three times per week (with placebo infusions matching ocrelizumab infusions every 24 weeks).

Experimental: Ocrelizumab - Ocrelizumab 600 mg intravenous (IV) as 300 mg infusions on Days 1 and 15 for the first dose and as a single infusion of 600 mg for all subsequent infusions every 24 weeks, with placebo injections matching interferon beta-1a SC three times per week.


Treatment: Drugs: Interferon beta-1a


Treatment: Drugs: Ocrelizumab-matching placebo


Treatment: Drugs: Ocrelizumab


Treatment: Drugs: Interferon beta-1a-matching placebo


Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Annualized Relapse Rate (ARR) in Participants With Relapsing Multiple Sclerosis (MS) at 96 Weeks - ARR was protocol-defined and calculated as the total number of relapses for all participants in the treatment group divided by the total participant-years of exposure to that treatment.
Timepoint [1] 0 0
Week 96
Secondary outcome [1] 0 0
Time to Onset of Confirmed Disability Progression (CDP) for at Least 12 Weeks During the Double-Blind Treatment Period - Disability progression was defined as an increase in the Expanded Disability Status Scale (EDSS) score of: A) >=1.0 point from the baseline EDSS score when the baseline score was less than or equal to (<=) 5.5 B) >=0.5 point from the baseline EDSS score when the baseline score was >5.5 The EDSS scale ranges from 0 (normal neurological exam) to 10 (death due to multiple sclerosis). This outcome measure was considered confirmatory only when results of both studies WA21092 and WA21093 were combined. Disability progression was considered confirmed when the increase in the EDSS was confirmed at a regularly scheduled visit at least 12 weeks after the initial documentation of neurological worsening. EDSS assessment and who were on treatment at time of clinical cut-off date were censored at the date of their last EDSS assessment.
Timepoint [1] 0 0
Week 108
Secondary outcome [2] 0 0
Number of T1 Gadolinium (Gd)-Enhancing Lesions as Detected by Brain Magnetic Resonance Imaging (MRI) During the Double-Blind Treatment - The total number of T1 gadolinium-enhancing lesions for all participants in the treatment group was calculated as the sum of the individual number of lesions at Weeks 24, 48, and 96.
Timepoint [2] 0 0
Baseline up to Week 96
Secondary outcome [3] 0 0
Number of New, and/or Enlarging T2 Hyperintense Lesions as Detected by Brain Magnetic Resonance Imaging (MRI) During the Double Blind Treatment - The total number of new and/or enlarging T2 lesions for all participants in the treatment group was calculated as the sum of the individual number of lesions at Weeks 24, 48, and 96.
Timepoint [3] 0 0
Baseline up to Week 96
Secondary outcome [4] 0 0
Percentage of Participants With Confirmed Disability Improvement (CDI) for at Least 12 Weeks - Disability improvement was assessed only for the subgroup of participants with a baseline EDSS score of >= 2.0. It was defined as a reduction in EDSS score of: A) >=1.0 from the baseline EDSS score when the baseline score was >=2 and <=5.5 B) >= 0.5 when the baseline EDSS score > 5.5. The EDSS scale ranges from 0 (normal neurological exam) to 10 (death due to multiple sclerosis). This outcome measure was considered confirmatory only when results of both studies WA21092 and WA21093 were combined.
Timepoint [4] 0 0
Week 96
Secondary outcome [5] 0 0
Time to Onset of Confirmed Disability Progression (CDP) for at Least 24 Weeks During the Double-Blind Treatment Period - Disability progression was defined as an increase in the Expanded Disability Status Scale (EDSS) score of: A) >=1.0 point from the baseline EDSS score when the baseline score was less than or equal to (<=) 5.5 B) >=0.5 point from the baseline EDSS score when the baseline score was >5.5 The EDSS scale ranges from 0 (normal neurological exam) to 10 (death due to multiple sclerosis). This outcome measure was considered confirmatory only when results of both studies WA21092 and WA21093 were combined. Disability progression was considered confirmed when the increase in the EDSS was confirmed at a regularly scheduled visit at least 24 weeks after the initial documentation of neurological worsening. Participants who had initial disability progression with no confirmatory EDSS assessment and who were on treatment at time of clinical cut-off date were censored at the date of their last EDSS assessment.
Timepoint [5] 0 0
Week 108
Secondary outcome [6] 0 0
Number of T1 Hypointense Lesions During the Double-Blind Treatment - The total number of new T1-Hypo-Intense Lesions (Chronic Black Holes) for all participants in the treatment group was calculated as the sum of the individual number of new lesions at Weeks 24, 48, and 96.
Timepoint [6] 0 0
Baseline up to Week 96
Secondary outcome [7] 0 0
Change From Baseline in Multiple Sclerosis Functional Composite (MSFC) Score to Week 96 - MSFC score consists of: A) Timed 25-Foot walk; B) 9-Hole Peg Test (9-HPT); and C) Paced Auditory Serial Addition Test (PASAT-3 version). The MSFCS is based on the concept that scores for these three dimensions (arm, leg, and cognitive function) are combined to create a single score (the MSFC) that can be used to detect change over time in a group of participants with MS. Since the three primary measures differ in what they actually measure, a common composite score for the three different measures i.e., Z- score was selected for the purpose. MSFC Score = {Z arm, average + Z leg, average + Z cognitive} / 3.0. The results from each of these three tests are transformed into Z-scores and averaged to yield a composite score for each participant at each time point. A score of +1 indicates that, on average, an individual scored 1 standard deviation (SD) better than the reference population and a score of -1 indicates that an individual scored 1 SD worse than the reference population.
Timepoint [7] 0 0
Baseline, Week 96
Secondary outcome [8] 0 0
Percent Change in Brain Volume as Detected by Brain Magnetic Resonance Imaging (MRI) From Week 24 to Week 96 - Brain volume was recorded as an absolute "normalized" value at the baseline visit then recorded at subsequent visits as a percentage change relative to the absolute value at the baseline visit. Therefore, brain volume at Week 24 was calculated as the brain volume at the baseline visit multiplied by 1 + ([percentage change in brain volume from baseline visit to Week 24]/100). Estimates are from analysis based on mixed-effect model of repeated measures (MMRM) using unstructured covariance matrix: Percentage Change = Brain Volume at Week 24 + Geographical Region (US vs. ROW) + Baseline EDSS (< 4.0 vs. >= 4.0) + Week + Treatment + Treatment*Week (repeated values over Week) + Brain Volume at Week 24*Week.
Timepoint [8] 0 0
From Week 24 up to Week 96
Secondary outcome [9] 0 0
Change From Baseline in Short Form Health Survey-36 (SF-36) Physical Component Summary (PCS) Score at Week 96 - The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the PCS and mental composite t-score (MCS). The range for all 8 domains as well as for the composite t- scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status.
Timepoint [9] 0 0
Baseline, Week 96
Secondary outcome [10] 0 0
Percentage of Participants Who Have No Evidence of Disease Activity (NEDA) up to Week 96 - NEDA was defined only for participants with a baseline EDSS score >=2.0. The EDSS scale ranges from 0 (normal neurological exam) to 10 (death due to multiple sclerosis). Participants who completed the 96- week treatment period were considered as having evidence of disease activity if at least one protocol- defined relapse (PDR), a confirmed disability progression (CDP) event or at least one MRI scan showing MRI activity (defined as Gd-enhancing T1 lesions, or new or enlarging T2 lesions) was reported during the 96-week treatment period, otherwise the participant was considered as having NEDA.
Timepoint [10] 0 0
Week 96
Secondary outcome [11] 0 0
Number of Participants With Adverse Events (AEs) - AEs included infusion related reactions (IRRs) and serious MS relapses, but excluded non-serious MS relapses. Serious Adverse Events (SAEs) included serious MS relapses and serious IRRs.
Timepoint [11] 0 0
Baseline up to Week 96
Secondary outcome [12] 0 0
Exposure to Ocrelizumab (Area Under the Concentration - Time Curve, AUC) - AUC represents total drug exposure for one dosing interval after the 4th dose.
Timepoint [12] 0 0
Pre-infusion at Weeks 1, 24, 48, 72; and 30 minutes post-infusion at Week 72; at any time during Weeks 84 and 96
Secondary outcome [13] 0 0
Number of Participants With Anti-Drug Antibodies (ADAs) to Ocrelizumab - Number of participants positive for anti-drug antibodies (ADAs) to ocrelizumab is the number of post- baseline evaluable participants determined to have treatment-induced ADA or treatment-enhanced ADA during the study period.
Timepoint [13] 0 0
Baseline up to week 96

Eligibility
Key inclusion criteria
- Diagnosis of multiple sclerosis, in accordance with the revised McDonald criteria
(2010)

- At least 2 documented clinical attacks within the last 2 years prior to screening or
one clinical attack in the years prior to screening (but not within 30 days prior to
screening)

- Neurologic stability for greater than or equal to (>=) 30 days prior to both screening
and baseline

- Expanded Disability Status Scale (EDSS) score 0 to 5.5 inclusive
Minimum age
18 Years
Maximum age
55 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Primary progressive multiple sclerosis

- Disease duration of more than 10 years in participants with EDSS less than or equal to
(<=) 2.0 at screening

- Contraindications for MRI

- Known presence of other neurological disorders which may mimic multiple sclerosis

- Pregnancy or lactation

- Requirement for chronic treatment with systemic corticosteroids or immunosuppressants
during the course of the study

- History of or currently active primary or secondary immunodeficiency

- History of severe allergic or anaphylactic reactions to humanized or murine monoclonal
antibodies

- Active infection, or history of or known presence of recurrent or chronic infection
(e.g., hepatitis B or C, human immunodeficiency virus [HIV], syphilis, tuberculosis)

- History of progressive multifocal leukoencephalopathy

- Contraindications to or intolerance of oral or iv corticosteroids

- Contraindications to Rebif or incompatibility with Rebif use

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Royal North Shore Hospital; Department of Neurology - St Leonards
Recruitment postcode(s) [1] 0 0
2065 - St Leonards
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Indiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Massachusetts
Country [8] 0 0
United States of America
State/province [8] 0 0
Michigan
Country [9] 0 0
United States of America
State/province [9] 0 0
Minnesota
Country [10] 0 0
United States of America
State/province [10] 0 0
Missouri
Country [11] 0 0
United States of America
State/province [11] 0 0
Nebraska
Country [12] 0 0
United States of America
State/province [12] 0 0
New Mexico
Country [13] 0 0
United States of America
State/province [13] 0 0
North Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Ohio
Country [15] 0 0
United States of America
State/province [15] 0 0
Oklahoma
Country [16] 0 0
United States of America
State/province [16] 0 0
Oregon
Country [17] 0 0
United States of America
State/province [17] 0 0
Pennsylvania
Country [18] 0 0
United States of America
State/province [18] 0 0
Texas
Country [19] 0 0
United States of America
State/province [19] 0 0
Vermont
Country [20] 0 0
United States of America
State/province [20] 0 0
Washington
Country [21] 0 0
Argentina
State/province [21] 0 0
Buenos Aires
Country [22] 0 0
Argentina
State/province [22] 0 0
Ciudad Autonoma Bs As
Country [23] 0 0
Argentina
State/province [23] 0 0
Rosario
Country [24] 0 0
Austria
State/province [24] 0 0
Linz
Country [25] 0 0
Belgium
State/province [25] 0 0
Brugge
Country [26] 0 0
Belgium
State/province [26] 0 0
Bruxelles
Country [27] 0 0
Belgium
State/province [27] 0 0
Roeselare
Country [28] 0 0
Brazil
State/province [28] 0 0
GO
Country [29] 0 0
Brazil
State/province [29] 0 0
RS
Country [30] 0 0
Brazil
State/province [30] 0 0
SC
Country [31] 0 0
Bulgaria
State/province [31] 0 0
Pleven
Country [32] 0 0
Bulgaria
State/province [32] 0 0
Sofia
Country [33] 0 0
Chile
State/province [33] 0 0
Valparaiso
Country [34] 0 0
Czechia
State/province [34] 0 0
Brno
Country [35] 0 0
Czechia
State/province [35] 0 0
Hradec Kralove
Country [36] 0 0
Czechia
State/province [36] 0 0
Jihlava
Country [37] 0 0
Czechia
State/province [37] 0 0
Pardubice
Country [38] 0 0
Czechia
State/province [38] 0 0
Prague
Country [39] 0 0
Czechia
State/province [39] 0 0
Teplice
Country [40] 0 0
Estonia
State/province [40] 0 0
Tallinn
Country [41] 0 0
Estonia
State/province [41] 0 0
Tartu
Country [42] 0 0
Finland
State/province [42] 0 0
Tampere
Country [43] 0 0
France
State/province [43] 0 0
Bordeaux
Country [44] 0 0
France
State/province [44] 0 0
Clermont Ferrand
Country [45] 0 0
France
State/province [45] 0 0
Nancy
Country [46] 0 0
France
State/province [46] 0 0
Nimes
Country [47] 0 0
France
State/province [47] 0 0
Strasbourg
Country [48] 0 0
Germany
State/province [48] 0 0
Berlin
Country [49] 0 0
Germany
State/province [49] 0 0
Dresden
Country [50] 0 0
Germany
State/province [50] 0 0
Hamburg
Country [51] 0 0
Germany
State/province [51] 0 0
Hannover
Country [52] 0 0
Germany
State/province [52] 0 0
Mainz
Country [53] 0 0
Germany
State/province [53] 0 0
Oldenburg
Country [54] 0 0
Germany
State/province [54] 0 0
Prien
Country [55] 0 0
Germany
State/province [55] 0 0
Rostock
Country [56] 0 0
Germany
State/province [56] 0 0
Tübingen
Country [57] 0 0
Germany
State/province [57] 0 0
Westerstede
Country [58] 0 0
Hungary
State/province [58] 0 0
Budapest
Country [59] 0 0
Hungary
State/province [59] 0 0
Tatabánya
Country [60] 0 0
Israel
State/province [60] 0 0
Ramat-Gan
Country [61] 0 0
Italy
State/province [61] 0 0
Lazio
Country [62] 0 0
Italy
State/province [62] 0 0
Lombardia
Country [63] 0 0
Italy
State/province [63] 0 0
Valle D'Aosta
Country [64] 0 0
Italy
State/province [64] 0 0
Veneto
Country [65] 0 0
Latvia
State/province [65] 0 0
Riga
Country [66] 0 0
Lithuania
State/province [66] 0 0
Kaunas
Country [67] 0 0
Lithuania
State/province [67] 0 0
Klaipeda
Country [68] 0 0
Lithuania
State/province [68] 0 0
Vilnius
Country [69] 0 0
Mexico
State/province [69] 0 0
Mexico
Country [70] 0 0
Mexico
State/province [70] 0 0
Monterrey
Country [71] 0 0
Netherlands
State/province [71] 0 0
Nieuwegein
Country [72] 0 0
Peru
State/province [72] 0 0
Callao
Country [73] 0 0
Peru
State/province [73] 0 0
Lima
Country [74] 0 0
Peru
State/province [74] 0 0
Pueblo Libre
Country [75] 0 0
Poland
State/province [75] 0 0
Gdansk
Country [76] 0 0
Poland
State/province [76] 0 0
Katowice
Country [77] 0 0
Poland
State/province [77] 0 0
Plewiska
Country [78] 0 0
Portugal
State/province [78] 0 0
Braga
Country [79] 0 0
Russian Federation
State/province [79] 0 0
Ekaterinburg
Country [80] 0 0
Russian Federation
State/province [80] 0 0
Kemerovo
Country [81] 0 0
Russian Federation
State/province [81] 0 0
Moscow
Country [82] 0 0
Russian Federation
State/province [82] 0 0
Novosibirsk
Country [83] 0 0
Russian Federation
State/province [83] 0 0
Samara
Country [84] 0 0
Russian Federation
State/province [84] 0 0
Smolensk
Country [85] 0 0
Russian Federation
State/province [85] 0 0
St. Petersburg
Country [86] 0 0
Russian Federation
State/province [86] 0 0
Tyumen
Country [87] 0 0
Serbia
State/province [87] 0 0
Belgrade
Country [88] 0 0
Serbia
State/province [88] 0 0
Kragujevac
Country [89] 0 0
Serbia
State/province [89] 0 0
NIS
Country [90] 0 0
Slovakia
State/province [90] 0 0
Bratislava
Country [91] 0 0
Slovakia
State/province [91] 0 0
Zilina
Country [92] 0 0
South Africa
State/province [92] 0 0
Durban
Country [93] 0 0
Spain
State/province [93] 0 0
Tenerife
Country [94] 0 0
Spain
State/province [94] 0 0
Vizcaya
Country [95] 0 0
Spain
State/province [95] 0 0
Madrid
Country [96] 0 0
Spain
State/province [96] 0 0
Sevilla
Country [97] 0 0
Switzerland
State/province [97] 0 0
Basel
Country [98] 0 0
Switzerland
State/province [98] 0 0
Lugano
Country [99] 0 0
Tunisia
State/province [99] 0 0
Mannouba
Country [100] 0 0
Tunisia
State/province [100] 0 0
Monastir
Country [101] 0 0
Tunisia
State/province [101] 0 0
Tunis
Country [102] 0 0
Ukraine
State/province [102] 0 0
Donetsk
Country [103] 0 0
Ukraine
State/province [103] 0 0
Kharkov
Country [104] 0 0
Ukraine
State/province [104] 0 0
Kyiv
Country [105] 0 0
Ukraine
State/province [105] 0 0
Lviv
Country [106] 0 0
Ukraine
State/province [106] 0 0
Vinnytsya
Country [107] 0 0
United Kingdom
State/province [107] 0 0
Liverpool
Country [108] 0 0
United Kingdom
State/province [108] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Hoffmann-La Roche
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This randomized, double-blind, double-dummy, parallel-group study will evaluate the efficacy
and safety of ocrelizumab in comparison with interferon beta-1a (Rebif) in participants with
relapsing multiple sclerosis. Participants will be randomized to receive either ocrelizumab
600 mg or matching placebo intravenous (IV) as 300 mg infusions on Days 1 and 15 for the
first dose and as a single infusion of 600 mg for all subsequent infusions every 24 weeks,
with placebo injections matching interferon beta-1a SC three times per week; or interferon
beta-1a 44 mcg SC injections three times per week (with placebo infusions matching
ocrelizumab infusions every 24 weeks). Planned duration of double-blind treatment is 96
weeks. Participants who complete the 96-week double-blind treatment will have an option to
enter a single-group, active-treatment, open-label extension period, providing they fulfill
the eligibility criteria.
Trial website
https://clinicaltrials.gov/show/NCT01247324
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications